Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ARFGEF2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ARFGEF2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ARFGEF2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARFGEF2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ARFGEF2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ARFGEF2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ARFGEF2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARFGEF2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00320111 | Lung | AIS | ARF protein signal transduction | 8/1849 | 19/18723 | 2.48e-04 | 4.83e-03 | 8 |
GO:00320121 | Lung | AIS | regulation of ARF protein signal transduction | 8/1849 | 19/18723 | 2.48e-04 | 4.83e-03 | 8 |
GO:009887612 | Lung | AIS | vesicle-mediated transport to the plasma membrane | 26/1849 | 136/18723 | 7.48e-04 | 1.07e-02 | 26 |
GO:004819312 | Lung | AIS | Golgi vesicle transport | 46/1849 | 296/18723 | 1.32e-03 | 1.64e-02 | 46 |
GO:000689312 | Lung | AIS | Golgi to plasma membrane transport | 13/1849 | 60/18723 | 5.04e-03 | 4.35e-02 | 13 |
GO:004819310 | Prostate | BPH | Golgi vesicle transport | 102/3107 | 296/18723 | 3.90e-14 | 4.56e-12 | 102 |
GO:00072658 | Prostate | BPH | Ras protein signal transduction | 101/3107 | 337/18723 | 5.64e-10 | 2.79e-08 | 101 |
GO:00160507 | Prostate | BPH | vesicle organization | 82/3107 | 300/18723 | 1.64e-06 | 2.78e-05 | 82 |
GO:00431129 | Prostate | BPH | receptor metabolic process | 51/3107 | 166/18723 | 4.49e-06 | 6.71e-05 | 51 |
GO:00988768 | Prostate | BPH | vesicle-mediated transport to the plasma membrane | 43/3107 | 136/18723 | 1.11e-05 | 1.51e-04 | 43 |
GO:00510568 | Prostate | BPH | regulation of small GTPase mediated signal transduction | 78/3107 | 302/18723 | 2.69e-05 | 3.16e-04 | 78 |
GO:00068928 | Prostate | BPH | post-Golgi vesicle-mediated transport | 34/3107 | 104/18723 | 4.14e-05 | 4.43e-04 | 34 |
GO:00465787 | Prostate | BPH | regulation of Ras protein signal transduction | 53/3107 | 189/18723 | 5.08e-05 | 5.24e-04 | 53 |
GO:00018199 | Prostate | BPH | positive regulation of cytokine production | 105/3107 | 467/18723 | 5.18e-04 | 3.66e-03 | 105 |
GO:00070326 | Prostate | BPH | endosome organization | 26/3107 | 82/18723 | 5.42e-04 | 3.81e-03 | 26 |
GO:00068937 | Prostate | BPH | Golgi to plasma membrane transport | 19/3107 | 60/18723 | 2.94e-03 | 1.54e-02 | 19 |
GO:004819314 | Prostate | Tumor | Golgi vesicle transport | 105/3246 | 296/18723 | 3.55e-14 | 4.33e-12 | 105 |
GO:000726514 | Prostate | Tumor | Ras protein signal transduction | 101/3246 | 337/18723 | 6.29e-09 | 2.44e-07 | 101 |
GO:001605012 | Prostate | Tumor | vesicle organization | 87/3246 | 300/18723 | 3.44e-07 | 7.71e-06 | 87 |
GO:004311215 | Prostate | Tumor | receptor metabolic process | 51/3246 | 166/18723 | 1.58e-05 | 2.13e-04 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARFGEF2 | SNV | Missense_Mutation | | c.1962N>G | p.Phe654Leu | p.F654L | Q9Y6D5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.2026N>A | p.Glu676Lys | p.E676K | Q9Y6D5 | protein_coding | tolerated(0.23) | benign(0.391) | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.817N>A | p.Glu273Lys | p.E273K | Q9Y6D5 | protein_coding | tolerated(0.46) | benign(0.014) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.2851N>C | p.Phe951Leu | p.F951L | Q9Y6D5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A1IL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARFGEF2 | SNV | Missense_Mutation | novel | c.1595N>A | p.Arg532His | p.R532H | Q9Y6D5 | protein_coding | tolerated(0.15) | probably_damaging(0.986) | TCGA-E9-A54Y-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARFGEF2 | SNV | Missense_Mutation | | c.3508G>A | p.Glu1170Lys | p.E1170K | Q9Y6D5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ARFGEF2 | insertion | In_Frame_Ins | novel | c.1886_1887insAAACCCCACTTCTACTAAAAA | p.Thr629_Val630insAsnProThrSerThrLysAsn | p.T629_V630insNPTSTKN | Q9Y6D5 | protein_coding | | | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ARFGEF2 | insertion | Nonsense_Mutation | novel | c.3959_3960insCGTGTTGTAAGCGCTTGATGAGTATTAATCT | p.Gly1321ValfsTer3 | p.G1321Vfs*3 | Q9Y6D5 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARFGEF2 | insertion | Nonsense_Mutation | novel | c.4621_4622insTCCCAAAACACTGAAATAGGGTGAAAA | p.Ala1541delinsValProLysHisTerAsnArgValLysThr | p.A1541delinsVPKH*NRVKT | Q9Y6D5 | protein_coding | | | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ARFGEF2 | insertion | Nonsense_Mutation | novel | c.2502_2503insTTTTAGTCATCTTTATAT | p.Glu834_Leu835insPheTerSerSerLeuTyr | p.E834_L835insF*SSLY | Q9Y6D5 | protein_coding | | | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD |